Registry-listed formulations

lirentelimab · chembl:CHEMBL4297878

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

7 source entries across 7 studies. This list may not include all unresolved or historical entries.

  • lirentelimab (AK002)Registry intervention

    Linked study entry; product equivalence not established

    View study and source
  • lirentelimab (AK002)Registry intervention

    Linked study entry; product equivalence not established

    View study and source
  • lirentelimab (AK002)Registry intervention

    Linked study entry; product equivalence not established

    View study and source
  • AK002Registry intervention

    Linked study entry; product equivalence not established

    View study and source
  • AK002Registry intervention

    Linked study entry; product equivalence not established

    View study and source
  • AK002Registry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Lirentelimab (AK002)Registry intervention

    Linked study entry; product equivalence not established

    View study and source

Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
71%(5/7)
Active Trials
0(0%)
Results Posted
120%(6 trials)
Terminated
2(25%)

Phase Distribution

Phase 3
4
50%
Phase 2
2
25%
Phase 1
1
13%
Phase 2/3
1
13%

Phase Distribution

1

Early Stage

3

Mid Stage

4

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
1(12.5%)
Phase 2Efficacy & side effects
2(25.0%)
Phase 2/3Combined phases
1(12.5%)
Phase 3Large-scale testing
4(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

62.5%

5 of 8 finished

Non-Completion Rate

37.5%

3 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(5)
Terminated(3)

Detailed Status

Completed5
Terminated2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (12.5%)
Phase 22 (25.0%)
Phase 2/31 (12.5%)
Phase 34 (50.0%)

Trials by Status

terminated225%
completed563%
withdrawn113%

Recent Activity

0 active trials
Showing 5 of 8
terminatedphase_2

A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic Dermatitis

NCT05155085
terminatedphase_2

A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria

NCT05528861
completedphase_3

An Extension Study of Lirentelimab in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)

NCT04620811
completedphase_3

A Study to Assess AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)

NCT04322604
completedphase_2_3

A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Esophagitis

NCT04322708
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT05155085Phase 2

A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic Dermatitis

Terminated
NCT05528861Phase 2

A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria

Terminated
NCT04620811Phase 3

An Extension Study of Lirentelimab in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)

Completed
NCT04322604Phase 3

A Study to Assess AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)

Completed
NCT04322708Phase 2/3

A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Esophagitis

Completed
NCT04856891Phase 3

A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis

Completed
NCT04324268Phase 1

A Study to Evaluate Safety, Tolerability, and Bioavailability of Subcutaneous Lirentelimab (AK002) in Adult Healthy Volunteers

Completed
NCT05152563Phase 3

A Study to Assess Subcutaneous AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis

Withdrawn

All 8 trials loaded

Drug Details

Intervention Type
Drug
Molecule Type
Antibody
Total Trials
8

External References

ChEMBL
CHEMBL4297878

Names & Codes

Research Codes

AK-002